Evidence map›Paper›PMID 36550142›Full record

ArticleScientific reports2022

Fibroblast growth factor-2 bound to specific dermal fibroblast-derived extracellular vesicles is protected from degradation.

Isabelle Petit, Ayelet Levy, Soline Estrach, Chloé C Féral, Andrea Gonçalves Trentin, Florent Dingli, Damarys Loew, Jieqiong Qu, Huiqing Zhou, Clotilde Théry and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Characterization ofMicroorganisms · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 3 countries.

Isabelle PetitSorbonne Université, Inserm U938, Centre de Recherche Saint-Antoine, 75012, Paris, France. isabelle.petit@inserm.fr.
Ayelet LevyINSERM U976, Hôpital St-Louis, 75010, Paris, France.
Soline EstrachUniversité Côte d'Azur, INSERM, CNRS, IRCAN, Faculté de Médecine, 06107, Nice, France.
Chloé C FéralUniversité Côte d'Azur, INSERM, CNRS, IRCAN, Faculté de Médecine, 06107, Nice, France.
Andrea Gonçalves TrentinFederal University of Santa Catarina, Florianópolis, Brazil.
Florent DingliInstitut Curie, PSL Research University, Centre de Recherche, Laboratoire de Spectrométrie de Masse Protéomique, 75005, Paris, France.
Damarys LoewInstitut Curie, PSL Research University, Centre de Recherche, Laboratoire de Spectrométrie de Masse Protéomique, 75005, Paris, France.
Jieqiong QuDepartment of Molecular Developmental Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University, 6525GA, Nijmegen, The Netherlands.
Huiqing ZhouDepartment of Molecular Developmental Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University, 6525GA, Nijmegen, The Netherlands.
Clotilde ThéryINSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.
Céline PrunierSorbonne Université, Inserm U938, Centre de Recherche Saint-Antoine, 75012, Paris, France.
Daniel AberdamINSERM U976, Hôpital St-Louis, 75010, Paris, France. daniel.aberdam@inserm.fr.
Olivier FerrignoSorbonne Université, Inserm U938, Centre de Recherche Saint-Antoine, 75012, Paris, France. olivier.ferrigno@inserm.fr.
Centre de Recherche Saint-Antoine · FRUniversité Paris Sciences et Lettres · FRRadboud Institute for Molecular Life Sciences · NLCentre de Recherche des Cordeliers · FRCentre National de la Recherche Scientifique · FRHôpital Saint-Louis · FRInstitut de Recherche sur le Cancer et le Vieillissement de Nice · FRUniversidade Federal de Santa Catarina · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast growth factor-2 (FGF2) has multiple roles in cutaneous wound healing but its natural low stability prevents the development of its use in skin repair therapies. Here we show that FGF2 binds the outer surface of dermal fibroblast (DF)-derived extracellular vesicles (EVs) and this association protects FGF2 from fast degradation. EVs isolated from DF cultured in the presence of FGF2 harbor FGF2 on their surface and FGF2 can bind purified EVs in absence of cells. Remarkably, FGF2 binding to EVs is restricted to a specific subpopulation of EVs, which do not express CD63 and CD81 markers. Treatment of DF with FGF2-EVs activated ERK and STAT signaling pathways and increased cell proliferation and migration. Local injection of FGF2-EVs improved wound healing in mice. We further demonstrated that binding to EVs protects FGF2 from both thermal and proteolytic degradation, thus maintaining FGF2 function. This suggests that EVs protect soluble factors from degradation and increase their stability and half-life. These results reveal a novel aspect of EV function and suggest EVs as a potential tool for delivering FGF2 in skin healing therapies.

Indexed as

Extracellular VesiclesFibroblast Growth Factor 2AnimalsCell ProliferationFibroblastsMiceWound HealingFibroblast Growth Factor 2

Identifiers

PMID36550142
PMCPMC9780220
OpenAlexW4312192874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.